Accession Number: | 0001209191-20-007505 |
Date: | 2020-02-05 |
Issuer: | VERTEX PHARMACEUTICALS INC / MA (VRTX) |
Original Submission Date: |
PARINI MICHAEL
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON, MA 02210
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2020-02-05 | A | 18,204 | a | $0.00 | 49,757 | direct | ||
COMMON STOCK | 2020-02-05 | A | 8,166 | a | $0.00 | 57,923 | direct | ||
COMMON STOCK | 2020-02-05 | A | 10,323 | a | $0.00 | 68,246 | direct | ||
COMMON STOCK | 2020-02-06 | M | 1,303 | a | $187.53 | 69,549 | direct | ||
COMMON STOCK | 2020-02-06 | M | 1,223 | a | $155.57 | 70,772 | direct | ||
COMMON STOCK | 2020-02-06 | S | 1,487 | d | $238.77 | 69,285 | direct | ||
COMMON STOCK | 2020-02-06 | S | 585 | d | $239.58 | 68,700 | direct | ||
COMMON STOCK | 2020-02-06 | S | 300 | d | $240.79 | 68,400 | direct | ||
COMMON STOCK | 2020-02-06 | S | 154 | d | $242.47 | 68,246 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 187.53 | 2020-02-06 | deemed execution date | M | 1,303 (d) | 2029-02-05 | common stock 1,303 | $187.53 | 15,642 | direct | ||
STOCK OPTION (RIGHT TO BUY) | 155.57 | 2020-02-06 | deemed execution date | M | 1,223 (d) | 2028-02-05 | common stock 1,223 | $155.57 | 9,783 | direct |
ID | footnote |
---|---|
f1 | represents earned performance shares with respect to a performance stock unit award granted on 02/03/2017 that contained performance-vesting requirements. the issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020 and the shares will vest on 02/10/2020. |
f2 | represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. the issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020. the earned performance shares will vest in installments beginning on 02/24/2020. |
f3 | restricted stock unit award that vests in installments beginning on 02/10/2021. |
f4 | transaction made pursuant to mr. parini's company-approved trading plan under rule 10b5-1. |
f5 | open market sales reported on this line occurred at a weighted average price of $238.77 (range $238.15 to $239.11). |
f6 | mr. parini undertakes to provide (upon request by the sec staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
f7 | open market sales reported on this line occurred at a weighted average price of $239.58 (range $239.17 to $240.11). |
f8 | open market sales reported on this line occurred at a weighted average price of $240.79 (range $240.51 to $241.05). |
f9 | the option vests in 16 quarterly installments from 02/06/2019. |
f10 | the option vests in 16 quarterly installments from 02/06/2018. |